Equities Analysts Offer Predictions for Prothena Q2 Earnings

Prothena Co. plc (NASDAQ:PRTA) – Analysts at Zacks Research raised their Q2 2025 EPS estimates for Prothena in a research note issued on Monday, January 27th. Zacks Research analyst E. Bagri now expects that the biotechnology company will post earnings per share of ($1.36) for the quarter, up from their prior estimate of ($1.38). The consensus estimate for Prothena’s current full-year earnings is ($2.24) per share. Zacks Research also issued estimates for Prothena’s Q4 2025 earnings at $0.53 EPS, FY2025 earnings at ($3.49) EPS, Q1 2026 earnings at ($1.41) EPS, Q2 2026 earnings at ($1.13) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($3.28) EPS.

Several other brokerages also recently commented on PRTA. Chardan Capital started coverage on shares of Prothena in a report on Friday, December 20th. They issued a “buy” rating and a $40.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $48.00 price target (down from $84.00) on shares of Prothena in a research report on Friday, December 20th. StockNews.com downgraded Prothena from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. Finally, Bank of America lowered their target price on Prothena from $26.00 to $22.00 and set a “neutral” rating on the stock in a research note on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Prothena has a consensus rating of “Moderate Buy” and a consensus price target of $46.50.

Prothena Stock Performance

PRTA stock opened at $14.70 on Thursday. Prothena has a 52-week low of $11.70 and a 52-week high of $31.03. The business has a 50-day simple moving average of $14.44 and a two-hundred day simple moving average of $17.80. The company has a market capitalization of $791.01 million, a P/E ratio of -5.93 and a beta of 0.10.

Prothena (NASDAQ:PRTA) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.08. The company had revenue of $0.97 million for the quarter, compared to analyst estimates of $1.22 million. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%. Prothena’s revenue for the quarter was down 98.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.38 earnings per share.

Hedge Funds Weigh In On Prothena

A number of institutional investors have recently made changes to their positions in PRTA. Orion Portfolio Solutions LLC lifted its stake in Prothena by 4.4% in the third quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company’s stock worth $293,000 after purchasing an additional 739 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Prothena by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 1,065 shares in the last quarter. Rhumbline Advisers raised its holdings in Prothena by 1.8% in the 4th quarter. Rhumbline Advisers now owns 67,115 shares of the biotechnology company’s stock worth $930,000 after purchasing an additional 1,175 shares in the last quarter. Pinnacle Associates Ltd. boosted its stake in shares of Prothena by 2.3% during the 3rd quarter. Pinnacle Associates Ltd. now owns 125,747 shares of the biotechnology company’s stock valued at $2,104,000 after purchasing an additional 2,847 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Prothena by 3.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 86,071 shares of the biotechnology company’s stock valued at $1,440,000 after acquiring an additional 3,163 shares in the last quarter. Institutional investors own 97.08% of the company’s stock.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.